Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Indian share markets trade firm
Mon, 4 Feb 01:30 pm

Indian share markets continued to trade strongly in the post noon trading session. Majority of the sectoral indices are trading positive with realty, auto and banking stocks leading in gains. Pharma, power and technology stocks are among the biggest losers.

BSE-Sensex is up 84 points and NSE-Nifty is trading up by 20 points. While BSE Mid Cap is down by 0.1%, BSE Small Cap index is up by a similar magnitude. The rupee is trading at 52.9 to the US dollar.

Most of the investment & finance stocks are trading in green with IFCI and Power Finance Corp being the biggest gainers. However, Infrastructure Development Finance Company (IDFC) and Indiabulls Financial Services are facing selling pressure. As per a leading financial daily, housing finance company HDFC is planning to raise external commercial borrowings to the tune of USD 500 m before March-end 2013. The company is awaiting approval from Reserve Bank of India (RBI). In FY13, RBI allowed builders to raise ECB up to USD 1 bn for low-cost affordable housing projects. Even Housing finance companies (HFCs) and National Housing Bank (NHB) can tap the ECB route for low-cost housing units. HDFC saw loan disbursements of around Rs 120 bn in the affordable homes segment in 2012. HDFC stock is currently up 2.2%.

Most of the foreign pharma stocks are trading in green with Sanofi India and Novartis being the major gainers. According to a leading financial daily, GlaxoSmithKline Pharmaceuticals (GSK Pharma) will be entering a deal with a multinational company to enter a new product line. As per the company, launching niche products from portfolios of other drug majors through in-licensing deals will continue to remain the company's strategy to grow operations locally. GSK Pharma currently has alliances with Daiichi-Sankyo for hypertension drug Olmesartan Medoxomil and with Astellas for anti-fungal drug Micafungin. The stock is currently trading up 0.6%.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets trade firm". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.